Primary Objective: To confirm the efficacy of RBX2660 as compared to a Placebo in preventing recurrent episodes of CDI through 8 weeks. Secondary Objective: To evaluate the sustained clinical response rate of RBX2660 as compared to Placebo after blinded treatment.
III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.
University of Colorado Hospital
Shelby Sullivan, MD
Protocol Number: 18-1344
More information available at ClinicalTrials.gov: NCT03244644
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers